Patisiran | search
Click here to view Patisiran news from 60+ newspapers.
Bookmark or Share- Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis ...Patisiran, an RNA interference therapeutic agent with a lipid nanoparticle delivery system, targets the common 3′ untranslated region of TTR messenger RNA in the liver to reduce circulating...
- Patisiran: First Global Approval - PubMedPatisiran has been developed by Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis (hATTR) in adults and subsequently approved in the EU for the treatment of hATTR in adults with stage 1 or 2 polyneuropathy.
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin ...Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin. In this phase 3 trial, we randomly assigned patients with hereditary...
- Patisiran Uses, Side Effects & Warnings - Drugs.comPatisiran is used to treat adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (damage of multiple nerves throughout the body). Patisiran may also be used for purposes not listed in this medication guide. Patisiran side effects.
- Patisiran - StatPearls - NCBI BookshelfPatisiran, a liposomal siRNA molecule, is used to treat patients with polyneuropathy (sensorimotor and autonomic neuropathy) and cardiomyopathy associated with hereditary transthyretin-mediated amyloidosis and wild-type transthyretin-mediated amyloidosis (ATTRwt).
More
